Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 23.57 CNY, compared to the current stock price of 19.89 CNY [4]. Core Insights - The company reported strong performance in H1 2025, with revenue of 1.599 billion CNY, a year-on-year increase of 11.99%, and a net profit of 374 million CNY, up 26.16% [1]. - The growth in the company's product lines, particularly the Wuling series and the Bailing series, indicates robust market expansion, with the Wuling series achieving sales of 897 million CNY (up 7.23%) and the Bailing series reaching 113 million CNY (up 38.51%) in H1 2025 [2]. - The company is actively enhancing its C-end market strategy, focusing on channel development and clinical value recognition, which is expected to drive sales growth [3]. Financial Performance - In H1 2025, the company achieved a net profit of approximately 372 million CNY after deducting non-recurring items, reflecting a growth of 27.24% year-on-year [1]. - The second quarter of 2025 saw a revenue of 775 million CNY, with a net profit of 192 million CNY, marking a year-on-year increase of 25.20% [1]. - The company anticipates revenue growth rates of 22.0%, 17.5%, and 16.2% for 2025 to 2027, with net profit growth rates of 30.2%, 27.2%, and 25.5% respectively [9]. Product Development and Market Expansion - The company is advancing its product development, with ongoing clinical trials and research for various products, including the Wuling series and the development of new health products using AI technology [8]. - The establishment of a joint research center with Zhejiang University aims to leverage cutting-edge technology for innovative product development [8]. - The company has made strategic investments, including a 20 million CNY stake in Lingyi Biotechnology, which is expected to enhance its long-term growth prospects [8].